
    
      The aim of this study is to document all patients with AML who are treated with the BCL2
      inhibitor Venetoclax outside a clinical trial in all hospitals participating in this registry
      study in a standardised manner. Data is collected retrospectively and multi-centric. It is
      neither a therapy study nor is the therapy influenced by this study.

        1. Systematic and uniform collection and documentation of all patients treated with the
           BCL2 inhibitor Venetoclax.

        2. Collection and integrative analysis of clinical data of included patients.

        3. Mutation analysis of available patient samples and correlation with clinical parameters.
    
  